Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

PURPOSE XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit in a phase I study of cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an MTC-enriched cohort, which is the focus of this article. PATIENTS AND METHODS A phase I dose-escalation study of oral cabozantinib was conducted in patients with advanced solid tumors. Primary end points included evaluation of safety, pharmacokinetics, and maximum-tolerated dose (MTD) determination. Additional end points included RECIST (Response Evaluation Criteria in Solid Tumors) response, pharmacodynamics, RET mutational status, and biomarker analyses. RESULTS Eighty-five patients were enrolled, including 37 with MTC. The MTD was 175 mg daily. Dose-limiting toxicities were grade 3 palmar plantar erythrodysesthesia (PPE), mucositis, and AST, ALT, and lipase elevations and grade 2 mucositis that resulted in dose interruption and reduction. Ten (29%) of 35 patients with MTC with measurable disease had a confirmed partial response. Overall, 18 patients experienced tumor shrinkage of 30% or more, including 17 (49%) of 35 patients with MTC with measurable disease. Additionally, 15 (41%) of 37 patients with MTC had stable disease (SD) for at least 6 months, resulting in SD for 6 months or longer or confirmed partial response in 68% of patients with MTC. CONCLUSION Cabozantinib has an acceptable safety profile and is active in MTC. Cabozantinib may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, VEGFR2, and RET. A global phase III pivotal study in MTC is ongoing (ClinicalTrials.gov number NCT00215605).

[1]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Iyer,et al.  Sorafenib: a clinical and pharmacologic review , 2010, Expert opinion on pharmacotherapy.

[3]  L. Paz-Ares,et al.  Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[4]  E. Baudin,et al.  Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). , 2010 .

[5]  M. Knopp,et al.  Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[7]  L. Stalpers,et al.  Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme , 2009, BMC Cancer.

[8]  W. You,et al.  Abstract A13: Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP‐Tag2 mice after inhibition of VEGFR plus c‐Met by XL184 , 2009 .

[9]  G. Wilding,et al.  Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Bastholt,et al.  Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Varsha Gandhi,et al.  MET receptor tyrosine kinase as a therapeutic anticancer target. , 2009, Cancer letters.

[12]  S. Sherman Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. , 2009, The Journal of clinical endocrinology and metabolism.

[13]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[14]  W. You,et al.  The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. , 2008, BMB reports.

[15]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Andrea B Troxel,et al.  Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[18]  I Judson,et al.  Advances in the treatment of gastrointestinal stromal tumours. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Christine Stephan,et al.  The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. , 2007, Cancer research.

[20]  D. Pfister,et al.  Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial , 2007 .

[21]  M. Stridsberg,et al.  A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. , 2007, Endocrine-related cancer.

[22]  B. Rini,et al.  Recent Progress in the Management of Advanced Renal Cell Carcinoma , 2007, CA: a cancer journal for clinicians.

[23]  Svend Kjær,et al.  Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain* , 2006, Journal of Biological Chemistry.

[24]  A. Joly 104 POSTER Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects , 2006 .

[25]  Kevin Wei,et al.  VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis , 2006, Nature Medicine.

[26]  P. Circosta,et al.  Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Fleisher,et al.  Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. , 2002, The Journal of clinical endocrinology and metabolism.

[28]  M. Schwab,et al.  Prognostic value of codon 918 (ATG→ACG) RET proto‐oncogene mutations in sporadic medullary thyroid carcinoma , 2001, International journal of cancer.

[29]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[30]  Q. Duh,et al.  Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. , 1997, The Journal of clinical endocrinology and metabolism.

[31]  M. Ivan,et al.  Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells , 1997, Oncogene.

[32]  S. Baylin,et al.  RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. , 1994, Human molecular genetics.

[33]  M. Schlumberger,et al.  Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy , 1990, Tumori.

[34]  D. Schoenfeld,et al.  A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma , 1985, Cancer.

[35]  M. Schott Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer , 2009 .

[36]  M. Gazouli,et al.  BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. , 2008, Anticancer research.

[37]  E. Baudin,et al.  New therapeutic approaches to treat medullary thyroid carcinoma , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[38]  M. Papotti,et al.  Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid , 2000, Endocrine pathology.

[39]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.